Deep Venous Thrombosis

Ann Intern Med. 2022 Sep;175(9):ITC129-ITC144. doi: 10.7326/AITC202209200. Epub 2022 Sep 13.

Abstract

Venous thromboembolism (VTE) is the third most common cardiovascular disorder, affecting up to 5% of the population. VTE commonly manifests as lower-extremity deep venous thrombosis (DVT) or pulmonary embolism. Half of these events are associated with a transient risk factor and may be preventable with prophylaxis. Direct oral anticoagulants are effective and safe and carry a lower risk for bleeding than vitamin K antagonists. Many patients with VTE will have a chronic disease requiring long-term anticoagulation. Postthrombotic syndrome affects 25% to 40% of patients with DVT and significantly impacts function and quality of life.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticoagulants / adverse effects
  • Humans
  • Quality of Life
  • Venous Thromboembolism* / drug therapy
  • Venous Thromboembolism* / epidemiology
  • Venous Thromboembolism* / prevention & control
  • Venous Thrombosis* / complications
  • Venous Thrombosis* / drug therapy
  • Venous Thrombosis* / prevention & control
  • Vitamin K / therapeutic use

Substances

  • Anticoagulants
  • Vitamin K